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E-mail address: tyamamot@ims.u-tokyo.ac.jp (T. YTob belongs to the anti-proliferative Tob/BTG family. The level of Tob throughout the cell cycle is
regulated by the SCF (Skp1/Cullin/F-box protein)Skp2 ubiquitin ligase (E3) complex. Here, we show
that Coronin7 (CRN7) is also involved in Tob degradation. We identiﬁed CRN7 as a Tob-interacting
molecule. A sequence containing two of the six WD motifs in the middle of CRN7 was responsible
for the interaction. CRN7 enhanced the polyubiquitination of Tob in vitro, and overexpression of
CRN7 promoted proteasome-dependent degradation of Tob. Furthermore, CRN7 interacted with Cul-
lin1 and Roc1 to form a novel SCF-like E3 complex, suggesting that Tob protein is regulated bymulti-
ple ubiquitination machineries.
Structured summary:
Cullin1 physically interacts with CRN7: shown by anti tag coimmunoprecipitation (view interaction)
Roc1 physically interacts with CRN7: shown by anti tag coimmunoprecipitation (view interaction)
CRN7 physically interacts with Tob1: shown by anti tag coimmunoprecipitation (view interaction)
CDC34 physically interacts with CRN7: shown by anti tag coimmunoprecipitation (view interaction)
Tob1 and CRN7 colocalize: shown by ﬂuorescence microscopy (view interaction)
Elongin B physically interacts with CRN7: shown by anti tag coimmunoprecipitation (view interaction)
Elongin C physically interacts with CRN7: shown by anti tag coimmunoprecipitation (view interaction)
Tob1 physically interacts with CRN7: shown by two hybrid (view interaction)
 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction However, in HeLa cells, degradation of Tob also occurs withoutTob, a member of the anti-proliferative Tob/BTG family of
proteins, is involved in the regulation of cell cycle progression at
the G1 phase [1–4]. The expression or phosphorylation of Tob
changes during the cell cycle and decreased expression and/or
phosphorylation have been detected in several human cancers,
including lung and thyroid cancer, compared with normal tissues
[3,5]. This suggests that the level of Tob expression is strictly reg-
ulated to maintain normal cell growth. It has been reported that
the ubiquitin–proteasome pathway is involved in the degradation
of Tob [6], and that SCFSkp2 functions as an E3 ubiquitin ligase for
Tob to regulate the cell cycle-dependent expression of Tob [7].chemical Societies. Published by E
cology, Institute of Medical
inato-ku, Tokyo 108-8639,
amamoto).the induction of Skp2, suggesting that other E3 ligases are involved
in Tob degradation [7].
Proteins targeted for degradation by the ubiquitin/proteasome
system are ﬁrst marked by covalent linkage to ubiquitin. Then,
ubiquitin is activated by a ubiquitin-activating enzyme (E1) in an
ATP-dependent manner. The activated ubiquitin is subsequently
transferred to a ubiquitin-conjugating enzyme (E2) and ultimately
binds to the substrate in a process mediated by a ubiquitin ligase
(E3) [8]. E3 ubiquitin ligases are often associated with multi-
protein complexes such as the SCF complex, the anaphase promot-
ing complex/cyclosome (APC/C), and the CBC complex [9–11]. The
SCF complexes are composed of Skp1, Cullin1, F-box proteins, and
the RING ﬁnger protein Roc1/Rbx1 [9,10]. The F-box proteins
include Skp2, which is important for G1 progression as it targets
various proteins such as p27kip1 and Tob [7,12–14]. The CBC com-
plex consists of multiple proteins such as Elongin B, Elongin C, and
a member of the Cullin family of proteins [11]. Elongin B/C
recognize the target proteins that are to be ubiquitinated [15,16].lsevier B.V. All rights reserved.
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all of which contain several WD repeat motifs [17]. Unlike the
other coronin family members which contain a single cluster of
WD repeats, CRN7 contains two clusters of WD repeat motifs.
CRN7 is localized mainly in the cytoplasm and the Golgi apparatus
[18]. RNA interference-mediated inhibition of CRN7 results in mor-
phological changes in the Golgi apparatus and the subsequent dis-
ruption of anterograde Golgi-to-plasma membrane transport [19].
Since CRN7 interacts with the clathrin adaptor AP-1, the function
of CRN7 may be important for clathrin-dependent membrane traf-
ﬁcking [18,19].
In this study, we identiﬁed CRN7 as a Tob-interacting protein.
CRN7 enhanced the ubiquitination of Tob in vitro and induced
the proteasome-dependent degradation of Tob in mammalian
cells. Furthermore, we show that CRN7 interacted with some com-
ponents of the ubiquitination machinery. These data suggest that
CRN7 functions as a component of an E3 ligase complex that tar-
gets Tob.2. Materials and methods
2.1. Yeast two-hybrid screen
The yeast two-hybrid screeningwas performed as described pre-
viously [20]. The N-terminal region of Tob (amino acids 2–236) was
used as bait to screen a human liver cDNA library (Clontech).
2.2. DNA constructs
The cDNAs encoding Tob and CRN7 (AK025674) were inserted
into the SRa promoter-driven mammalian expression vector
pME18S-6Myc [21] and the CMV promoter-containing pRK-Flag
vector [20], respectively. For the expression of the CRN7 deletion
mutants, mutated cDNA fragments were polymerase chain reac-
tion (PCR)-ampliﬁed and then inserted into the pRK-Flag vector.
2.3. Preparation of recombinant proteins
Recombinant 6His-E2 proteins and the glutathione S-transfer-
ase (GST) fused Tob fragment (aa 1–170) [3] were expressed in
BL21 Escherichia coli and puriﬁed using Ni–NTA sepharose beads
(Qiagen) or glutathione-sepharose beads (GE Healthcare), respec-
tively. In vitro translated Tob was prepared using a TNT Quick kit
(Promega) according to the manufacturer’s instructions. Recombi-
nant E1 enzyme was purchased from Boston Biochem.
2.4. In situ hybridization and Northern blot analysis
In situ hybridization was performed as described previously
[22]. The cDNA fragment corresponding to the N-terminal region
of the mouse CRN7 cDNA (amino acids 1–66) was ampliﬁed with
PCR, and then inserted into the pBluescript II. Antisense and sense
cRNA probes were generated from the plasmid by in vitro tran-
scription in the presence of [35S]UTP. Parasagittal sections of whole
embryos were prepared from day 18.5 C57BL/6 mouse embryos,
and subjected to hybridization with cRNA probes as described
[22]. Northern blot analysis was performed as described previously
[21]. The CRN7 cDNA encoding amino acids 1–166 was used as a
probe.
2.5. Antibodies
Rabbit polyclonal antibodies were generated against a synthetic
peptide of CRN7 (amino acids 907–923) and were puriﬁed from the
antiserum using a peptide-conjugated afﬁnity column. The anti-Tob (4B1) monoclonal antibody was from IBL. These antibodies
are not useful to detect endogenous proteins with immunocyto-
chemistry. Anti-Myc (9E10), anti-ubiquitin (1B3) and anti-Flag
(M2) monoclonal antibodies were purchased from Santa Cruz Bio-
technology, MBL and Sigma, respectively.
2.6. Cell culture, transfection, immunoprecipitation, and
immunoblotting
HEK293T and COS7 cells were maintained in Dulbecco’s modi-
ﬁed Eagle’s medium supplemented with 10% fetal bovine serum
in 5% CO2 at 37 C. The cells were transfected with the expression
plasmids by FuGENE transfection reagent (Roche). Immunoprecip-
itation, immunoblotting and immunocytochemistry were per-
formed as described previously [3].
2.7. In vitro ubiquitination assay
In vitro ubiquitination assays were performed as described pre-
viously [23]. In brief, GST-CRN7 was puriﬁed from the lysate of
HEK293T cells transfected with the GST-CRN7 expression construct
using glutathione sepharose beads. After being washed with lysis
buffer (20 mM Tris–HCl [pH 7.5], 150 mM NaCl, 10 mM NaF, 1 mM
EDTA, 1% NP-40), the beads were suspended in 50 ll of buffer A
(40 mM Tris–HCl [pH 7.4], 5 mM MgCl2, 2 mM dithiothreitol, 2 lM
ATP), and 15 lg of bovine ubiquitin (Sigma), 1 lg of recombinant
E2 protein, and recombinant Tob were added to the tube. The
mixtures were incubated for 1.5 h at 30 C, and the reaction prod-
ucts were analyzed by SDS–PAGE followed by immunoblotting.3. Results
3.1. Identiﬁcation of CRN7 as a Tob-interacting protein
To identify proteins that interact with Tob, a yeast two-hybrid
screen was performed using a partial cDNA sequence of Tob (amino
acids 2–236) as bait. After screening a human liver cDNA library, we
obtained several positive clones, including a clone that encoded the
carboxy-terminal 341 amino acids of CRN7 (amino acids 584–925,
Fig. 1A). To examine whether CRN7 interacts with Tob in mamma-
lian cells, we carried out co-immunoprecipitation experiments. The
expression vector encoding 6Myc-tagged Tob was transfected into
COS7 cells together with the construct expressing Flag-tagged
CRN7. Lysates of the transfected cells were immunoprecipitated
with an anti-Flag antibody, and the immunoprecipitates were ana-
lyzed by immunoblottingwith an anti-Myc antibody.While Tob co-
immunoprecipitated with full-length CRN7 and with the C-termi-
nal half of CRN7 (CRN-C: amino acids 584–925), Tob did not co-
immunoprecipitate with the N-terminal half of CRN7 (CRN-N: ami-
no acids 1–583) (Fig. 1B). To further narrow the interacting domain,
we generated two additional CRN7 deletionmutants, CRN-C1 (ami-
no acids 584–770) and CRN-C2 (amino acids 584–720) (Fig. 1A). Co-
immunoprecipitation experiments with these mutant proteins
showed that amino acids 584–720 of CRN7 which contain two
WD repeats, were sufﬁcient for the interaction with Tob (Fig. 1C).
We also examined the subcellular localization of exogenously ex-
pressed Tob and CRN7 in cells. The results show that Tob is ob-
served in both nucleus and cytoplasm and CRN7 is mainly
localized in the cytoplasm. Co-localization of Tob and CRN7 is de-
tected in the cytoplasm (Fig. 1D).
3.2. Expression pattern of CRN7
Next, we examined the expression of CRN7 mRNA in multiple
human tissues using Northern blots. CRN7 mRNA was clearly ex-
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Fig. 1. CRN7 interacts with Tob. (A) Schematic diagrams of the CRN7 deletion mutants. (B and C) CRN7 interacts with Tob in mammalian cells. COS7 cells were transfected
with constructs expressing Tob-6Myc and Flag-CRN7 or the indicated deletion mutants. Cell lysates were prepared and immunoprecipitated (IP) with an anti-Flag antibody.
The immunoprecipitates were immunoblotted (IB) with an anti-Myc antibody. (D) Co-localization of Tob with CRN7 in COS7 cells. Exogenously expressed Tob and Flag-CRN7
in COS7 cells were detected with immunoﬂuorescence using anti-Tob and anti-Flag antibodies. (E) Tissue speciﬁc expression of crn7 mRNA. Human MTN Blot membranes
were hybridized with a 32P-labeled crn7 probe. (F) Expression of crn7 mRNA in mouse embryos. In situ hybridization was performed on parasagittal sections of whole E18.5
mouse embryos. Br, brain; Tg, trigeminal ganglion; Th, thymus; Si, small intestine; G, spinal ganglions. (G) Validation of polyclonal antibodies against CRN7. COS7 cells were
transfected with a construct expressing Flag-tagged full-length CRN7 (lane 2) or CRN-C (lane 3), and the cell lysates were analyzed by immunoblotting with an anti-Flag
antibody (left) or the anti-CRN7 antibodies (right). The lysates of untransfected cells were loaded in the ﬁrst lane of each blot. (H) The expression of CRN7 in mouse tissues
and human cell lines. The indicated lysates were analyzed by immunoblotting with an anti-CRN7 antibody. BM: bone marrow.
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and small intestine in humans (Fig. 1E). Overall, the data were con-
sistent with the previously published data [18], although there
were some inconsistencies. For example, we observed that the
expression of CRN7 mRNA was high in the testes and very low in
the kidney, but others have shown high expression in the kidney
and low expression in the testes [18]. This inconsistency might be
due to differences in the species analyzed: we analyzed expression
in human tissues but others have used mouse tissues. In situ
hybridization of parasagittal sections of whole mouse embryos
demonstrated that CRN7 mRNA was highly expressed in the thy-
mus, small intestine, spinal ganglions, trigeminal ganglion, and cen-
tral nervous system (Fig. 1F). To analyze the expression of the CRN7
protein, we generated rabbit polyclonal antibodies against amino
acids 907–923 of CRN7 and validated the speciﬁcity of the antibod-
ies by demonstrating speciﬁc recognition of CRN7 expressed exog-
enously in COS7 cells (Fig. 1G). The antibodies reacted with an
approximately 100 kDa protein expressed in mouse splenocytes
and thymocytes but not with proteins expressed in the bone mar-
row and liver (Fig. 1H). We assumed that the 100 kDa protein
was the endogenous CRN7 protein. The antibodies also recognized
a similarly sized protein in Raji cells, a human B-cell line (Fig. 1H).
3.3. CRN7 induces the degradation of Tob
The above co-immunoprecipitation experiments were per-
formed by expressing C-terminally Myc-tagged Tob together withFlag-tagged CRN7 (Fig. 1B and C). We also expressed non-tagged
Tob protein for co-immunoprecipitation assays. We found that
non-tagged Tob was only minimally detected by immunoblotting
when expressed together with full-length CRN7 or CRN7-C,
whereas the protein was easily detected when expressed without
concomitant CRN7 expression (Fig. 2A). It should be noted that
the C-terminally tagged Tob proteins is resistant to proteasome-
dependent degradation [24]. To examine the possibility that non-
tagged Tob was degraded in the presence of CRN7, we treated
the transfected cells with the proteasome inhibitor MG132. The
expression level of Tob was comparable in the MG132-treated cells
in the presence and absence of CRN7 or CRN-C (Fig. 2A), suggesting
that CRN7 induces the proteasome-dependent degradation of Tob.
To identify the region of CRN7 required for Tob degradation, we
transfected the cells with the CRN7 deletion mutants together with
Tob. As the CRN-C1 mutant, but not the CRN-N and CRN-C2
mutants, promoted Tob degradation (Fig. 2B), the region between
amino acids 720 and 770 of CRN7 is necessary for Tob degradation
(Fig. 2C, gray box). This region is different from the Tob interaction
domain (Fig. 1).
3.4. CRN7 forms ubiquitin ligase complexes
Since the ectopic expression of E3 ubiquitin ligases results in
the decreased expression of their target protein, we speculated
that CRN7 could function as an E3 ubiquitin ligase for Tob. CRN7
does not contain a RING ﬁnger domain or a HECT domain, two
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Fig. 2. CRN7 induces the proteasome-dependent degradation of Tob. (A) COS7 cells were co-transfected with the Tob expression vector and the Flag-CRN7 expression vector,
the Flag-CRN-C vector, or the control vector. The cells were treated with the proteasome inhibitor MG132 (50 lM) or with DMSO for 2 h before cell lysates were prepared. The
cell lysates were then analyzed by immunoblotting for Tob and CRN7. (B) The effects of deletion in CRN7 on Tob degradation. COS7 cells were co-transfected with a Tob
expression vector and the indicated CRN7 expression constructs, and immunoblots were performed as in (A). (C) The summarized results from the co-immunoprecipitation
analyses and the investigation of CRN7-induced degradation of Tob. The C-terminal region of CRN7 is important in the interaction with Tob and in promoting Tob
degradation.
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forms an ubiquitin ligase complex with multiple proteins, similar
to those found in the SCF, APC/C, or CBC complexes. Since the Cullin
family of proteins act as scaffold proteins for ubiquitin ligases, we
investigated the interaction between CRN7 and Cullin proteins by
co-immunoprecipitation. COS7 cells were co-transfected with the
CRN7 expression plasmid and the expression vector encoding var-
ious Flag-tagged Cullin proteins. The Cullin proteins were then
immunoprecipitated from the lysates of the transfected cells with
anti-Flag antibody. As shown in Fig. 3A, CRN7 was co-immunopre-
cipitated with Cullin1, but not with the other Cullin proteins. As
Cullin1 is a component of the SCF complex, we examined the inter-
action between CRN7 and the other proteins in the SCF complex,
including RING ﬁnger proteins. CRN7 was associated with the RING
ﬁnger proteins Roc1 and Cdc34 E2, but not with UbcH5c (Fig. 3B).
Although Skp1mediates the interaction between Cullin1 and the F-
box proteins, CRN7 did not interact with Skp1, suggesting that
CRN7 forms a novel E3 ligase complex. As the amino acid sequence
of a region of CRN7 (amino acids 552–579), which partly overlaps
with one of the C-terminal WD repeat motifs (Fig. 3C), is similar to
the SOCS box sequence, we speculated that CRN7 could replace the
SOCS function found in the CBC ubiquitin ligase complex [16]. As
the SOCS box sequence is necessary for the interaction of SOCS
family proteins with Elongin B and Elongin C, we examined
whether CRN7 interacts with Elongin B and Elongin C using
co-immunoprecipitation experiments. We found that the interac-
tion was seen only when the cells were treated with the MG132
proteasome inhibitor (Fig. 3D). These suggest that CRN7 forms a
novel CBC-like ubiquitin ligase complex that contains Elongin B,
Elongin C and Cullin1.
3.5. CRN7 promotes the ubiquitination of Tob in vitro
Formation of E3-like complex by CRN7 with several molecules
provided the possibility that CRN7 is involved in the ubiquitination
of Tob. To examine this, we performed an in vitro ubiquitination
assay. We transfected HEK293T cells with a construct expressing
GST-CRN7 and puriﬁed the CRN7-associated proteins from the celllysates (Fig. 4A). The puriﬁed proteins were then subjected to an
in vitro ubiquitination assay using recombinant Tob protein as
the substrate and Cdc34, which interacts with CRN7 in mammalian
cells, as an E2 enzyme (Fig. 3B). Immunoblotting of the reaction
products with an anti-Tob antibody detected a shift in the electro-
phoretic mobility of Tob (Fig. 4B). To conﬁrm the speciﬁcity of the
reaction, we incubated Tob and GST-CRN7 with different combina-
tions of E1, E2, and ubiquitin. Immunoblotting of the reaction
products showed an shift in the electrophoretic mobility of Tob
only when all of the molecules were present, and depletion of
any one component resulted in no observable shift (Fig. 4C, left),
suggesting that Tob was ubiquitinated in the presence of GST-
CRN7. The electrophoretic mobility shift of Tob in an SDS poly-
acrylamide gel was also detected by immunoblotting a duplicate
blot with an anti-ubiquitin antibody (Fig. 4C, right). These data
suggest that CRN7 acts as an E3 ubiquitin ligase for Tob. However,
in vitro ubiquitination of Tob promoted by the CRN7 complex is
very weak. As it was difﬁcult to detect endogenous Cullin1 in the
glutathione-sepharose precipitates of the above ubiquitination
assay, we assume that CRN7-mediated Tob ubiquitination and
CRN7-Cullin1 interaction likely occur in some speciﬁc conditions.
4. Discussion
We identiﬁed CRN7 as a Tob-interacting protein and found that
CRN7 promoted the ubiquitination and subsequent proteasome-
mediated degradation of Tob. The C-terminal half of CRN7 was
responsible for Tob degradation and was more effective in promot-
ing degradation than full-length CRN7 (Fig. 2B). It is possible that
the N-terminal half of CRN7 has a negative effect on Tob degrada-
tion and that a conformational change in CRN7 in response to
cellular signaling modulates the activity. CRN7 is known to partic-
ipate in the regulation of Golgi trafﬁcking [18,19]; however, its
involvement in proteosome-mediated degradation has not been
reported. We show here for the ﬁrst time that CRN7 forms a novel
E3 ligase complex. Like WD motif-containing F-box proteins in SCF
complexes, the WD motifs of CRN7 could be important for the
target recognition. Indeed, two of the six WD motifs of CRN7 are
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M. Watanabe et al. / FEBS Letters 585 (2011) 65–70 69located in the sequence required for the interaction with Tob
(Fig. 2). It should be noted that Tob undergoes rapid turnover
(the half-life is 15–30 min) and is strongly ubiquitinated even inthe absence of CRN7 in COS7 cells (Supplementary Figure), sug-
gesting that CRN7 reduces total amount of Tob when CRN7 is acti-
vated or the expression is induced by any extracellular stimulation.
70 M. Watanabe et al. / FEBS Letters 585 (2011) 65–70Identifying the extracellular stimuli which increase the amount of
CRN7 or promote the interaction between CRN7 and Cullin1 would
help better understand the molecular mechanism by which CRN7
induced Tob degradation.
The SCF and CBC ligases are similar in that they form Cullin/
Roc1-based complexes [9–11]. In contrast to the SCF complex, in
which Skp1 mediates the interaction between Cullin1 and F-box
proteins, CRN7 interacted with Cullin1, but not with Skp1
(Fig. 3). Interestingly, we noticed that CRN7 has a SOCS box-like
motif that may be important for the interaction with Elongin B
and Elongin C. Indeed, the co-immunoprecipitation experiments
showed that CRN7 interacts with Elongin B and Elongin C
(Fig. 3D). Therefore, we hypothesize that CRN7 forms a unique Cul-
lin1/Roc1-based E3 complex. As the interaction between CRN7 and
Elongin B/Elongin C was detected only in the presence of MG132,
other labile proteins may mediate the interaction.
Skp2, an F box protein, is a critical regulator of cell cycle pro-
gression because it targets several tumor suppressor proteins
[25]. Tob, a negative regulator of the cell cycle progression, is also
the target of Skp2 [7], indicating the involvement of the Skp2-med-
iated degradation of Tob in cell cycle regulation. Because enforced
expression of CRN7 does not have any effect on cell cycle progres-
sion (data not shown), CRN7-mediated degradation of Tob could be
important in other contexts. Since CRN7 is strongly expressed in
the cells and tissues of the immune system, such as the thymus,
in both human and mice (Fig. 1) [18], and since Tob is involved
in T-cell responses [26], it would be interesting to investigate the
biological signiﬁcance of CRN7-mediated Tob degradation on im-
mune function.
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